MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
Unknown status
Hospices Civils de Lyon
Phase 2
2005-02-01
In this study, treosulfan is evaluated for conditioning in allogenic stem cell
transplantation. The procedure and the follow-up are the same as in standard allogenic
transplant.
The donor is unrelated (identical HLA). The graft is haematological peripheral blood stem
cell.
The conditioning with reduced intensity is: fludarabine (from day -6 to day -2), treosulfan
(from day -6 to day -4) and thymoglobuline (from day -2 to day -1).
Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Completed
medac GmbH
Phase 1/Phase 2
2005-06-01
RATIONALE: Drugs used in chemotherapy, such as treosulfan and fludarabine, work in different
ways to stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Giving treosulfan and fludarabine together with a donor bone marrow transplant or a
peripheral stem cell transplant may be an effective treatment for acute myeloid leukemia,
acute lymphoblastic leukemia, or myelodysplastic syndrome.
PURPOSE: This phase II trial is studying giving treosulfan together with fludarabine to see
how well it works in treating patients who are undergoing a donor stem cell transplant for
acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
